

## DAFTAR PUSTAKA

- Akram, A.R., Chalmers, J.D., Taylor, J.K., Rutherford, J., Singanayagam, A., dan Hill, A.T., 2013. An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia. *Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases*, **19**: 1174–1180.
- Aliberti, S., Blasi, F., Zanaboni, A.M., Peyrani, P., Tarsia, P., Gaito, S., dkk., 2010. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. *European Respiratory Journal*, **36**: 128–134.
- Aliberti, S., Zanaboni, A.M., Wiemken, T., Nahas, A., Uppatla, S., Morlacchi, L.C., dkk., 2013. Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. *European Respiratory Journal*, **42**: 742–749.
- Allredge, B.K., Corelli, R.L., dan Ernst, M.E., 2012. *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins.
- Almirall, J., Rofes, L., Serra-Prat, M., Icart, R., Palomera, E., Arreola, V., dkk., 2013. Oropharyngeal dysphagia is a risk factor for community-acquired pneumonia in the elderly. *The European Respiratory Journal*, **41**: 923–928.
- Almirall, J., Serra-Prat, M., Bolívar, I., Palomera, E., Roig, J., Boixeda, R., dkk., 2015. Professions and Working Conditions Associated With Community-Acquired Pneumonia. *Archivos De Bronconeumologia*, **51**: 627–631.
- Andayani, T.M., 2013. *Farmakoekonomi Prinsip Dan Metodologi*. Bursa Ilmu, Yogyakarta.
- Arnold, R.J.G. (Editor), 2010. *Pharmacoeconomics: From Theory to Practice*, Drug discovery series. Taylor & Francis, Boca Raton, FL.
- Aronson, J.K. (Editor), 2015. *Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions*, 16th edition. ed. Elsevier Science, Amsterdam Boston Heidelberg.
- Azmi, S., Aljunid, S.M., Maimaiti, N., Ali, A.-A., Muhammad Nur, A., De Rosas-Valera, M., dkk., 2016. Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. *International Journal of Infectious Diseases*, **49**: 87–93.
- Baldwin, D.R., Wise, R., Andrews, J.M., Ashby, J.P., dan Honeybourne, D., 1990. Azithromycin concentrations at the sites of pulmonary infection. *The European Respiratory Journal*, **3**: 886–890.

- Bartolomé, M., Almirall, J., Morera, J., Pera, G., Ortún, V., Bassa, J., dkk., 2004. A population-based study of the costs of care for community-acquired pneumonia. *The European Respiratory Journal*, **23**: 610–616.
- Baskaran, V., Murray, R.L., Hunter, A., Lim, W.S., dan McKeever, T.M., 2019. Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. *PLoS ONE*, **14**: e0220204.
- Bauer, T.T., Welte, T., Ernen, C., Schlosser, B.M., Thate-Waschke, I., Zeeuw, J. de, dkk., 2005. Cost Analyses of Community-Acquired Pneumonia From the Hospital Perspective. *CHEST*, **128**: 2238–2246.
- Bell, B.G., Schellevis, F., Stobberingh, E., Goossens, H., dan Pringle, M., 2014. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infectious Diseases*, **14**: 13.
- Blum, C.A., Nigro, N., Briel, M., Schuetz, P., Ullmer, E., Suter-Widmer, I., dkk., 2015. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet (London, England)*, **385**: 1511–1518.
- Braeken, D.C., Rohde, G.G., Franssen, F.M., Driessen, J.H., van Staa, T.P., Souverein, P.C., dkk., 2017. Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom. *International Journal of Chronic Obstructive Pulmonary Disease*, **12**: 2425–2432.
- Brunetti, V.C., Ayele, H.T., Yu, O.H.Y., Ernst, P., dan Fillion, K.B., 2021. Type 2 diabetes mellitus and risk of community-acquired pneumonia: a systematic review and meta-analysis of observational studies. *CMAJ Open*, **9**: E62–E70.
- Brunton, L.L., Knollmann, B.C., dan Hilal-Dandan, R. (Editor), 2018. *Goodman & Gilman's the Pharmacological Basis of Therapeutics*, Thirteenth edition. ed. McGraw Hill Medical, New York.
- Cannizzaro, D.N., Naughton, L.F., Freeman, M.Z., Martin, L., Bennett, C.L., dan Bove, C., 2021. A New Criterion for Fluoroquinolone-Associated Disability Diagnosis: Functional Gastrointestinal Disorders. *Medicina*, **57**: 1371.
- Charlson, M.E., Carrozzino, D., Guidi, J., dan Patierno, C., 2022. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. *Psychotherapy and Psychosomatics*, **91**: 8–35.
- Chi, Y.-L., Blecher, M., Chalkidou, K., Culyer, A., Claxton, K., Edoka, I., dkk., 2020. What next after GDP-based cost-effectiveness thresholds?

- Choi, S.-H., Cesar, A., Snow, T.A.C., Saleem, N., Arulkumaran, N., dan Singer, M., 2023. Respiratory fluoroquinolone monotherapy vs.  $\beta$ -lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. *International Journal of Antimicrobial Agents*, **62**: 106905.
- Choi, Y., Lim, H.-S., Chung, D., Choi, J., dan Yoon, D., 2018. Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice. *BioMed Research International*, **2018**: 1574806.
- Chou, H.-W., Wang, J.-L., Chang, C.-H., Lai, C.-L., Lai, M.-S., dan Chan, K.A., 2015. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and  $\beta$ -lactam/ $\beta$ -lactamase inhibitors: a Taiwanese nationwide study. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **60**: 566–577.
- Cillóniz, C., Cardozo, C., dan García-Vidal, C., 2018a. Epidemiology, pathophysiology, and microbiology of communityacquired pneumonia. *Annals of Research Hospitals*, **2**: .
- Cillóniz, C., Rodríguez-Hurtado, D., dan Torres, A., 2018b. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. *Medical Sciences*, **6**: 35.
- Corica, B., Tartaglia, F., D’Amico, T., Romiti, G.F., dan Cangemi, R., 2022. Sex and gender differences in community-acquired pneumonia. *Internal and Emergency Medicine*, **17**: 1575–1588.
- Dinh, A., Duran, C., Ropers, J., Bouchand, F., Davido, B., Deconinck, L., dkk., 2021a. Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. *JAMA network open*, **4**: e2129566.
- Dinh, A., Ropers, J., Duran, C., Davido, B., Deconinck, L., Matt, M., dkk., 2021b. Discontinuing  $\beta$ -lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. *Lancet (London, England)*, **397**: 1195–1203.
- Dunbar, L.M., Wunderink, R.G., Habib, M.P., Smith, L.G., Tennenberg, A.M., Khashab, M.M., dkk., 2003. High-Dose, Short-Course Levofloxacin for Community-Acquired Pneumonia: A New Treatment Paradig. *Clinical Infectious Diseases*, **37**: 752–760.
- Egger, M.E., Myers, J.A., Arnold, F.W., Pass, L.A., Ramirez, J.A., dan Brock, G.N., 2016. Cost effectiveness of adherence to IDSA/ATS guidelines in

elderly patients hospitalized for Community-Acquired Pneumonia. *BMC medical informatics and decision making*, **16**: 34.

Egi, M., Makino, S., dan Mizobuchi, S., 2018. Management of fever in critically ill patients with infection. *Journal of Emergency and Critical Care Medicine*, **2**: .

Farida, H., Severin, J.A., Gasem, M.H., Keuter, M., van den Broek, P., Hermans, P.W.M., dkk., 2013. Nasopharyngeal carriage of *Klebsiella pneumoniae* and other Gram-negative bacilli in pneumonia-prone age groups in Semarang, Indonesia. *Journal of Clinical Microbiology*, **51**: 1614–1616.

Farida, Y., Khoiry, Q.A., Hanafi, M., dan Maryani, M., 2022. Cost-effectiveness analysis of empiric antibiotics in hospitalized community-acquired Pneumonia. *Pharmaciana*, **12**: 83.

FDA, 2016. FDA Drug Safety Podcast: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects.

File, T.M., Bartlet, J.G., dan Thomer, A., 2018. Treatment of community-acquired pneumonia in adults who require hospitalization. *Up to Date Wolters Kluwer*, tersedia di <http://www.uptodate.com/contents/treatment-of-community-acquired-pneumonia-in-adults-who-require-hospitalization> diakses tanggal, **28**: .

File, T.M. dan Marrie, T.J., 2010. Burden of community-acquired pneumonia in North American adults. *Postgraduate Medicine*, **122**: 130–141.

Frank, E., Liu, J., Kinasewitz, G., Moran, G.J., Oross, M.P., Olson, W.H., dkk., 2002. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. *Clinical Therapeutics*, **24**: 1292–1308.

Garin, N., Felix, G., Chuard, C., Genné, D., Carballo, S., Hugli, O., dkk., 2016. Predictors and Implications of Early Clinical Stability in Patients Hospitalized for Moderately Severe Community-Acquired Pneumonia. *PLOS ONE*, **11**: e0157350.

Gotfried, M.H., Danziger, L.H., dan Rodvold, K.A., 2001. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. *Chest*, **119**: 1114–1122.

Halm, E.A., Fine, M.J., Kapoor, W.N., Singer, D.E., Marrie, T.J., dan Siu, A.L., 2002. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. *Archives of Internal Medicine*, **162**: 1278–1284.

Halm, E.A., Fine, M.J., Marrie, T.J., Coley, C.M., Kapoor, W.N., Obrosky, D.S.,

- dkk., 1998. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. *JAMA*, **279**: 1452–1457.
- Han, X., Chen, L., Wang, Y., Li, H., Wang, H., Xing, X., dkk., 2021. Cost Effectiveness of Different Initial Antimicrobial Regimens for Elderly Community-Acquired Pneumonia Patients in General Ward. *Infection and Drug Resistance*, **14**: 1845–1853.
- Han, X., Liu, X., Chen, L., Wang, Y., Li, H., Zhou, F., dkk., 2020. Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients. *BMC infectious diseases*, **20**: 668.
- Heffernan, A.J., Sime, F.B., Lim, S.M.S., Adiraju, S., Wallis, S.C., Lipman, J., dkk., 2022. Pharmacodynamics of ceftriaxone for the treatment of methicillin-susceptible *Staphylococcus aureus*: is it a viable treatment option? *International Journal of Antimicrobial Agents*, **59**: 106537.
- Izadi, M., Dadsetan, B., Najafi, Z., Jafari, S., Mazaheri, E., Dadras, O., dkk., 2018. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients. *Recent Patents on Anti-Infective Drug Discovery*, **13**: 228–239.
- Jain, S., Self, W.H., Wunderink, R.G., Fakhraan, S., Balk, R., Bramley, A.M., dkk., 2015. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *The New England Journal of Medicine*, **373**: 415–427.
- Kato, H., Hagihara, M., Morikawa, Y., Asai, N., Mikamo, H., dan Iwamoto, T., 2022. Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia. *Antibiotics (Basel, Switzerland)*, **11**: 983.
- Katzung, B.G. (Editor), 2018. *Basic & Clinical Pharmacology*, Fourteenth edition. ed, A Lange medical book. McGraw-Hill Education, New York Chicago San Francisco Athens London Madrid Mexico City Milan New Delhi Singapore Sydney Toronto.
- Kementerian Kesehatan RI, 2011. Peraturan Menteri Kesehatan Nomor 2406/MENKES/PER/XII/2011 tentang Pedoman Umum Penggunaan Antibiotik.
- Kementerian Kesehatan RI, 2013. *Pedoman Penerapan Kajian Farmakoeкономи. Kementerian Kesehatan Republik Indonesia.*, Jakarta.
- Kementerian Kesehatan RI, 2019. *Laporan Nasional Riset Kesehatan Dasar (RISKESDAS) Tahun 2018*. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan (LPB), Jakarta.

- Kim, S.H., Song, J.-H., Chung, D.R., Thamlikitkul, V., Yang, Y., Wang, H., dkk., 2012. Changing Trends in Antimicrobial Resistance and Serotypes of *Streptococcus pneumoniae* Isolates in Asian Countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. *Antimicrobial Agents and Chemotherapy*, **56**: 1418–1426.
- Kosar, F., Alici, D.E., Hacibedel, B., Arpınar Yigitbas, B., Golabi, P., dan Cuhadaroglu, C., 2017. Burden of community-acquired pneumonia in adults over 18 y of age. *Human Vaccines & Immunotherapeutics*, **13**: 1673–1680.
- Kovaleva, A., Remmelts, H.H.F., Rijkers, G.T., Hoepelman, A.I.M., Biesma, D.H., dan Oosterheert, J.J., 2012. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. *The Journal of Antimicrobial Chemotherapy*, **67**: 530–540.
- Lee, J.H., Kim, S.W., Kim, J.H., Ryu, Y.J., dan Chang, J.H., 2012. High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study. *Clinical Drug Investigation*, **32**: 569–576.
- Lemeshow, S., Jr, D.W.H., Klar, J., dan Lwanga, S.K., 1990. *Adequacy of Sample Size in Health Studies*, 1st edition. ed. Wiley, Chichester England ; New York : New York, NY, USA.
- Liang, L., Moore, B., dan Soni, A., 2020. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2017, dalam: *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*. Agency for Healthcare Research and Quality (US), Rockville (MD).
- Lim, W.S., Baudouin, S.V., George, R.C., Hill, A.T., Jamieson, C., Jeune, I.L., dkk., 2009. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax*, **64**: iii1–iii55.
- Lim, W.S., Eerden, M.M. van der, Laing, R., Boersma, W.G., Karalus, N., Town, G.I., dkk., 2003. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax*, **58**: 377–382.
- Lin, S.-H., Perng, D.-W., Chen, C.-P., Chai, W.-H., Yeh, C.-S., Kor, C.-T., dkk., 2016. Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease. *International Journal of Chronic Obstructive Pulmonary Disease*, **11**: 3051–3058.
- Lister, P.D., 2002. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of *Streptococcus pneumoniae*. *Diagnostic Microbiology and Infectious Disease*, **44**: 43–49.
- Liu, J., 2013. Impact of diabetes mellitus on pneumonia mortality in a senior



population: results from the NHANES III follow-up study. *Journal of Geriatric Cardiology : JGC*, **10**: 267–271.

Liu, S., Tong, X., Ma, Y., Wang, D., Huang, J., Zhang, L., dkk., 2019. Respiratory Fluoroquinolones Monotherapy vs.  $\beta$ -Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis. *Frontiers in Pharmacology*, **10**: 489.

López-de-Andrés, A., Albaladejo-Vicente, R., de Miguel-Diez, J., Hernández-Barrera, V., Ji, Z., Zamorano-León, J.J., dkk., 2021. Gender differences in incidence and in-hospital outcomes of community-acquired, ventilator-associated and nonventilator hospital-acquired pneumonia in Spain. *International Journal of Clinical Practice*, **75**: e13762.

Loscalzo, J. (Editor), 2016. *Harrison's Pulmonary and Critical Care Medicine*, Third edition. ed. McGraw-Hill Education Medical, Boston, Massachusetts.

Luna, C.M., Palma, I., Niederman, M.S., Membriani, E., Giovini, V., Wiemken, T.L., dkk., 2016. The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia. *Annals of the American Thoracic Society*, **13**: 1519–1526.

Mahendra, M., Jayaraj, B.S., Limaye, S., Chaya, S.K., Dhar, R., dan Mahesh, P.A., 2018. Factors influencing severity of community-acquired pneumonia. *Lung India: Official Organ of Indian Chest Society*, **35**: 284–289.

Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., dkk., 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **44 Suppl 2**: S27–72.

Martinez-Garcia, M.A., Faner, R., Oscullo, G., de la Rosa, D., Soler-Cataluña, J.-J., Ballester, M., dkk., 2020. Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis. *American Journal of Respiratory and Critical Care Medicine*, **201**: 1078–1085.

McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., dkk., 2021. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*, **42**: 3599–3726.

Meduri, G.U., Shih, M.-C., Bridges, L., Martin, T.J., El-Solh, A., Seam, N., dkk.,

2022. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. *Intensive Care Medicine*, **48**: 1009–1023.
- Menéndez, R., Martinez, R., Reyes, S., Mensa, J., Polverino, E., Filella, X., dkk., 2009. Stability in community-acquired pneumonia: one step forward with markers? *Thorax*, **64**: 987–992.
- Menéndez, R., Torres, A., Rodríguez de Castro, F., Zalacaín, R., Aspa, J., Martín Villascclaras, J.J., dkk., 2004. Reaching Stability in Community-Acquired Pneumonia: The Effects of the Severity of Disease, Treatment, and the Characteristics of Patients. *Clinical Infectious Diseases*, **39**: 1783–1790.
- Merigian, K.S., Hedges, J.R., Roberts, J.R., Childress, R.A., Niehaus, M.A., dan Franklin, N., 1988. Use of abbreviated mental status examination in the initial assessment of overdose patients. *Archives of Emergency Medicine*, **5**: 139–145.
- Metlay, J.P., Waterer, G.W., Long, A.C., Anzueto, A., Brozek, J., Crothers, K., dkk., 2019. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *American Journal of Respiratory and Critical Care Medicine*, **200**: e45–e67.
- Mohanty, S., Johnson, K.D., Yu, K.C., Watts, J.A., dan Gupta, V., 2022. A Multicenter Evaluation of Trends in Antimicrobial Resistance Among *Streptococcus pneumoniae* Isolates From Adults in the United States. *Open Forum Infectious Diseases*, **9**: ofac420.
- Molinos, L., Clemente, M.G., Miranda, B., Alvarez, C., Busto, B. del, Cocina, B.R., dkk., 2009. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. *Journal of Infection*, **58**: 417–424.
- Moorthy, N., Raghavendra, N., dan Venkatarathnamma, P.N., 2008. Levofloxacin-induced acute psychosis. *Indian Journal of Psychiatry*, **50**: 57–58.
- Mortensen, E.M., Halm, E.A., Pugh, M.J., Copeland, L.A., Metersky, M., Fine, M.J., dkk., 2014. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. *JAMA*, **311**: 2199–2208.
- Muller, L.M. a. J., Gorter, K.J., Hak, E., Goudzwaard, W.L., Schellevis, F.G., Hoepelman, A.I.M., dkk., 2005. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **41**: 281–288.



- Nafae, R.M., Ragab, M.I., Amany, F.M., dan Rashed, S.B., 2013. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. *Egyptian Journal of Chest Diseases and Tuberculosis*, **62**: 439–445.
- Nguyen, M.T.N., Saito, N., dan Wagatsuma, Y., 2019. The effect of comorbidities for the prognosis of community-acquired pneumonia: an epidemiologic study using a hospital surveillance in Japan. *BMC Research Notes*, **12**: 817.
- Noreddin, A.M., Hoban, D.J., dan Zhanel, G.G., 2005. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for *Streptococcus pneumoniae*. *International Journal of Antimicrobial Agents*, **26**: 120–125.
- Olson, G. dan Davis, A.M., 2020. Diagnosis and Treatment of Adults With Community-Acquired Pneumonia. *JAMA*, **323**: 885.
- Ostermann, H., Garau, J., Medina, J., Pascual, E., McBride, K., Blasi, F., dkk., 2014. Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study. *BMC pulmonary medicine*, **14**: 36.
- Owens, R.C. dan Nolin, T.D., 2006. Antimicrobial-associated QT interval prolongation: pointes of interest. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **43**: 1603–1611.
- Peleg, A.Y., Weerathna, T., McCarthy, J.S., dan Davis, T.M.E., 2007. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. *Diabetes/Metabolism Research and Reviews*, **23**: 3–13.
- Perhimpunan Dokter Paru Indonesia (PDPI), 2014. *Pneumonia Komunitas: Pedoman Diagnosis Dan Penatalaksanaan Di Indonesia*, Edisi II. ed. Perhimpunan Dokter Paru Indonesia, Jakarta.
- Phua, J., Ngerng, W.J., dan Lim, T.K., 2010. The impact of a delay in intensive care unit admission for community-acquired pneumonia. *European Respiratory Journal*, **36**: 826–833.
- Postma, D.F., Spitoni, C., van Werkhoven, C.H., van Elden, L.J.R., Oosterheert, J.J., dan Bonten, M.J.M., 2019. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. *BMC infectious diseases*, **19**: 17.
- Postma, D.F., van Werkhoven, C.H., van Elden, L.J.R., Thijsen, S.F.T., Hoepelman, A.I.M., Kluytmans, J.A.J.W., dkk., 2015. Antibiotic treatment strategies for community-acquired pneumonia in adults. *The New England*

*Journal of Medicine*, **372**: 1312–1323.

Purba, A.K., Ascobat, P., Muchtar, A., Wulandari, L., Rosyid, A.N., Purwono, P.B., dkk., 2019. Multidrug-Resistant Infections Among Hospitalized Adults With Community-Acquired Pneumonia In An Indonesian Tertiary Referral Hospital. *Infection and Drug Resistance*, **12**: 3663–3675.

Radji, M., 2014. *Antibiotik Dan Kemoterapi*. Penerbit Buku Kedokteran EGC, Jakarta.

Ramirez, J.A., Wiemken, T.L., Peyrani, P., Arnold, F.W., Kelley, R., Mattingly, W.A., dkk., 2017. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **65**: 1806–1812.

Rascati, K.L., 2014. *Essentials of Pharmacoeconomics*, Second edition. ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.

Rello, J., Rodriguez, A., Torres, A., Roig, J., Sole-Violan, J., Garnacho-Montero, J., dkk., 2006. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. *The European Respiratory Journal*, **27**: 1210–1216.

Restrepo, M.I., Sibila, O., dan Anzueto, A., 2018. Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. *Tuberculosis and Respiratory Diseases*, **81**: 187–197.

Roth, G.A., Abate, D., Abate, K.H., Abay, S.M., Abbafati, C., Abbasi, N., dkk., 2018. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*, **392**: 1736–1788.

Sapey, E. dan Stockley, R.A., 2006. COPD exacerbations · 2: Aetiology. *Thorax*, **61**: 250–258.

Savitri, A.A., Nuryastuti, T., dan Puspitasari, I., 2022. Analisis Rasionalitas Penggunaan Antibiotik Empiris Dan Definitif Pada Terapi Pneumonia Dan Profil Antibiotikogram di Rumah Sakit Akademik Universitas Gadjah Mada. *Majalah Farmaseutik*, **18**: .

Spellberg, B., 2016. The New Antibiotic Mantra—“Shorter Is Better.” *JAMA internal medicine*, **176**: 1254–1255.

Strauß, R., Ewig, S., Richter, K., König, T., Heller, G., dan T. Bauer, T., 2014. The Prognostic Significance of Respiratory Rate in Patients With Pneumonia. *Deutsches Ärzteblatt International*, **111**: 503–508.

- Suratini, S., Sauriasari, R., dan Hamadah, F., 2017. COST-EFFECTIVENESS ANALYSIS OF CEFTRIAZONE-AZITHROMYCIN COMBINATION AND SINGLE LEVOFLOXACIN AS EMPIRICAL ANTIBIOTICS IN COMMUNITY-ACQUIRED PNEUMONIA INPATIENTS AT PERSAHABATAN HOSPITAL. *Asian Journal of Pharmaceutical and Clinical Research*, **10**: 118.
- Tenório, M.C. dos S., Graciliano, N.G., Moura, F.A., Oliveira, A.C.M. de, dan Goulart, M.O.F., 2021. N-Acetylcysteine (NAC): Impacts on Human Health. *Antioxidants*, **10**: 967.
- The World Bank, 2022. 'GDP per capita (current US\$) - Indonesia', *The World Bank*. URL: <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=ID> (diakses tanggal 7/4/2024).
- Torres, A., Peetermans, W.E., Viegli, G., dan Blasi, F., 2013. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. *Thorax*, **68**: 1057–1065.
- Torres, A., Sibila, O., Ferrer, M., Polverino, E., Menendez, R., Mensa, J., dkk., 2015. Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response: A Randomized Clinical Trial. *JAMA*, **313**: 677–686.
- Tsaganos, T., Tseti, I.K., Tziolos, N., Soumelas, G., Koupetori, M., Pyrpasopoulou, A., dkk., 2017. Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection. *British Journal of Clinical Pharmacology*, **83**: 742–750.
- Uranga, A., España, P.P., Bilbao, A., Quintana, J.M., Arriaga, I., Intxausti, M., dkk., 2016. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. *JAMA Internal Medicine*, **176**: 1257–1265.
- van Werkhoven, C.H., Postma, D.F., Mangen, M.-J.J., Oosterheert, J.J., Bonten, M.J.M., dan CAP-START study group, 2017. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial. *BMC infectious diseases*, **17**: 52.
- World Health Organization, 2019. 'Global health estimates: Leading causes of death', . URL: <https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/gho-leading-causes-of-death> (diakses tanggal 4/12/2022).
- Yadegarynia, D., Tehrani, S., Nejad Maghsoudi, F., Shojaeian, F., dan Keyvanfar,

- A., 2022. Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study. *Iranian Journal of Microbiology*, **14**: 458–465.
- Zaki, H.A., Hamdi Alkahlout, B., Shaban, E., Mohamed, E.H., Basharat, K., Elsayed, W.A.E., dkk., 2023. The Battle of the Pneumonia Predictors: A Comprehensive Meta-Analysis Comparing the Pneumonia Severity Index (PSI) and the CURB-65 Score in Predicting Mortality and the Need for ICU Support. *Cureus*, **15**: e42672.
- Zervos, M., Mandell, L.A., Vrooman, P.S., Andrews, C.P., McIvor, A., Abdulla, R.H., dkk., 2004. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. *Treatments in Respiratory Medicine*, **3**: 329–336.
- Zhang, Q., Ju, Y., Ma, Y., dan Wang, T., 2018. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial. *Medicine*, **97**: e13087.
- Zhang, Y.-Q., Zou, S.-L., Zhao, H., Zhang, M.-M., dan Han, C.-L., 2018. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. *The American Journal of Emergency Medicine*, **36**: 1759–1765.
- Zhao, T., Chen, L.-A., Wang, P., Tian, G., Ye, F., Zhu, H., dkk., 2016. A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia. *Journal of Thoracic Disease*, **8**: .